Outcomes in COVID-19 baloxavir studies

0 0.5 1 1.5+ All studies -200% 1 20 Improvement, Studies, Patients Relative Risk Ventilation -200% 1 20 ICU admission -200% 1 20 Viral clearance -600% 1 20 RCTs -200% 1 20 Late -200% 1 20 Baloxavir for COVID-19 c19early.org December 2025 Favorsbaloxavir Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Lou (RCT) -200% 3.00 [0.14-65.9] ventilation 1/10 0/10 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.5 Late treatment -200% 3.00 [0.14-65.9] 1/10 0/10 200% higher risk All studies -200% 3.00 [0.14-65.9] 1/10 0/10 200% higher risk 1 baloxavir COVID-19 study c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.5 Effect extraction pre-specified(most serious outcome) Favors baloxavir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Lou (RCT) -200% 3.00 [0.14-65.9] 1/10 0/10 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.5 Late treatment -200% 3.00 [0.14-65.9] 1/10 0/10 200% higher risk All studies -200% 3.00 [0.14-65.9] 1/10 0/10 200% higher risk 1 baloxavir COVID-19 mechanical ventilation result c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.5 Favors baloxavir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Lou (RCT) -200% 3.00 [0.14-65.9] 1/10 0/10 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.5 Late treatment -200% 3.00 [0.14-65.9] 1/10 0/10 200% higher risk All studies -200% 3.00 [0.14-65.9] 1/10 0/10 200% higher risk 1 baloxavir COVID-19 ICU result c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.5 Favors baloxavir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Lou (RCT) -200% 3.00 [0.14-65.9] ventilation 1/10 0/10 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.5 Late treatment -200% 3.00 [0.14-65.9] 1/10 0/10 200% higher risk All studies -200% 3.00 [0.14-65.9] 1/10 0/10 200% higher risk 1 baloxavir COVID-19 serious outcome c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.5 Effect extraction pre-specified(most serious outcome) Favors baloxavir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Lou (RCT) 20% 0.80 [0.30-2.13] no recov. 4/10 5/10 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.67 Late treatment 20% 0.80 [0.30-2.13] 4/10 5/10 20% lower risk All studies 20% 0.80 [0.30-2.13] 4/10 5/10 20% lower risk 1 baloxavir COVID-19 recovery result c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.67 Favors baloxavir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Lou (RCT) -600% 7.00 [0.41-120] viral+ 3/10 0/10 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.18 Late treatment -600% 7.00 [0.41-120] 3/10 0/10 600% higher risk All studies -600% 7.00 [0.41-120] 3/10 0/10 600% higher risk 1 baloxavir COVID-19 viral clearance result c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.18 Favors baloxavir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Lou (RCT) -200% 3.00 [0.14-65.9] ventilation 1/10 0/10 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.5 Late treatment -200% 3.00 [0.14-65.9] 1/10 0/10 200% higher risk All studies -200% 3.00 [0.14-65.9] 1/10 0/10 200% higher risk 1 baloxavir COVID-19 Randomized Controlled Trial c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.5 Effect extraction pre-specified(most serious outcome) Favors baloxavir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Lou (RCT) -200% 3.00 [0.14-65.9] ventilation 1/10 0/10 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.5 Late treatment -200% 3.00 [0.14-65.9] 1/10 0/10 200% higher risk All studies -200% 3.00 [0.14-65.9] 1/10 0/10 200% higher risk 1 baloxavir COVID-19 peer reviewed studies c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.5 Effect extraction pre-specified(most serious outcome) Favors baloxavir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Lou (RCT) -200% 3.00 [0.14-65.9] ventilation 1/10 0/10 Improvement, RR [CI] Treatment Control Lou (RCT) -200% 3.00 [0.14-65.9] ICU 1/10 0/10 Lou (RCT) 20% 0.80 [0.30-2.13] no recov. 4/10 5/10 Lou (RCT) 0% 1.00 [0.75-1.34] no recov. 9/10 9/10 Lou (RCT) -600% 7.00 [0.41-120] viral+ 3/10 0/10 Lou (RCT) 20% 0.80 [0.30-2.13] viral+ 4/10 5/10 Baloxavir COVID-19 outcomes c19early.org December 2025 Favors baloxavir Favors control